

### SUBJECT INDEX TO VOLUME 3

Accessory glands .....	348	Bivalent B/E rgp120 HIV vaccine .....	24
Advanced HIV-1 disease .....	224	phase III efficacy trial of .....	24
other factors for .....	224	Blood-brain barrier (BBB) .....	306
AIDS .....	31,199,261,320	Blood screening .....	371
etiology of chronic diarrhea during .....	199	using combined EIA antigen/antibody (vironostika	
impact on women/children .....	31	Ag/Ab) test .....	372
pathogenesis of viruses associated with .....	322	using exa virload test V2 .....	372
perturbation of cytokine network in .....	261	using Roche amplicor HIV-1 DNA test .....	372
RAF/MEK/ERK inhibitors in treating .....	322	using Roche amplicor HIV-1 RNA test .....	372
role for RAF signaling in .....	322	Blood-testis barrier .....	346
studies with non-human primates .....	199	effect on HIV-1 viral protein gp 120 on CCR5 gene	
viruses associated with .....	320	by .....	280
AIDS vaccines .....	157	C3d .....	191
AAV vectors based .....	161	cell-mediated immune responses by .....	195
adenovirus vectors based .....	163	effect on immune responses .....	191
alphavirus particle-based vectors for .....	162	CC/CXC chemokines .....	361
attenuated poxvirus vectors based .....	159	associated with mother-to-child HIV-1 transmission	361
clinical trials of .....	173,174	in breast milk .....	361
delivered by AAV vectors .....	173	measurement of .....	362
delivered by alphavirus vectors .....	174	maternal viral load of .....	362
delivered by non-replicating viral vectors .....	164	CCR5 antagonists .....	294
delivered by retroviral vectors .....	174	Chronic diarrhea .....	199
delivered by SV40/HSV-1 amplicon vectors .....	174	by bacteria .....	201
HIV delivered by adenoviral vectors .....	172	by <i>Brachyspira</i> .....	202
HSV-1 amplicon vectors based .....	164	by <i>Campylobacter</i> .....	202
non-replicating viral vector-based .....	157	by <i>Candida albicans</i> .....	201
preclinical studies of .....	173,174	by <i>Clostridium difficile</i> .....	201
retroviral vectors for .....	163	by <i>Cryptosporidium parvum</i> .....	202
safety/toxicity of .....	165	by <i>Cytomegalovirus (CMV)</i> .....	200
strategies to develop viral vector-based .....	169	by <i>Escherichia</i> .....	201
SV40 vectors for .....	163	by fungi .....	201
virus structure/vector development for .....	159	by <i>Helicobacter pylorji</i> .....	202
AIDSVAX B/E vaccine .....	23	by <i>Microsporidia</i> .....	201
phase I/II evaluation of safety/immunogenicity of .....	23	by <i>Mycobacterium</i> sp .....	201
ALVAC-based HIV vaccines .....	171	by other enteric viruses .....	201
clinical trials of .....	171	by other opportunistic microorganisms/parasites .....	202
pre-clinical studies of .....	171	by <i>pylori</i> .....	202
Anti-Env antibodies .....	192	by protozoa .....	202
ELISA for detection of .....	192	by <i>Salmonella</i> .....	201
Anti-HIV agents .....	289	by <i>Shigella</i> .....	201
development of .....	289	by viruses .....	200
targeting dynamic supramolecular mechanism .....	289	functions of .....	330
Anti-HIV drug targets .....	81	immunological/physiological processes leading to .....	199
viral enzymes as .....	81	opportunistic/pathogenic agents in .....	200
Antiretroviral drugs .....	207	structure features of .....	329
physico-chemical characteristics of .....	211	studies with non-human primates .....	199
compartmentalization/penetration by .....	207	Coreceptor .....	53
concentrations in semen .....	212	usage in HIV-1 cellular tropism .....	53
APOBEC3G .....	340	CXCR4/CCR5 antagonists .....	289
drug development based on .....	342	entry/fusion inhibitors based on .....	289
incorporation into HIV particles .....	340	from T140 .....	289
Attenuated HIV-1 .....	377	Cytokine therapy .....	261
implications for vaccine development .....	377	in HIV-infected AIDS patients .....	261
Aventis pasteur live recombinant ALVAC-HIV .....	25		
phase I/II trial of .....	25		

Cytopathic R5 HIV-1 .....	56	in non-AIDS related malignancies .....	141
ENV-receptor interactions by .....	56	in reconstitution syndrome .....	138
DNA sequencing analysis .....	382	internal medicine of .....	140
thyl.2 gene deletion by .....	382	role of ethnicity .....	134
DNA vaccines .....	192	role of gender .....	134
<i>in vitro</i> expression of .....	192	socioeconomic factors in .....	134
Epididymis .....	348	Histone acetyl transferases .....	63
Eukaryotic cells .....	331	regulation of TAR/TAT/P-TEFB interactions .....	63
regulatory RNAs in .....	331	tat acetylation by .....	63
Exa VIR reverse transcriptase activity assay .....	371	HIV .....	107,243
alternative approach to .....	371	antibody binding studies in .....	109
blood screening using .....	371	CD4+ T cell apoptosis in .....	248
effect on intracellular Ca <sup>2+</sup> measurement .....	284	CD8+ T cell apoptosis in .....	249
in synthesis of opioid $\mu$ receptor .....	282	entry of .....	246
Foreign gene sequences .....	377	formulation of vaccine cocktails for .....	108
implications for vaccine development .....	377	multi-envelope vaccine approaches to .....	108
rapid size dependent deletion of .....	377	pandemic of .....	107
Fowlpox-based HIV vaccines .....	171	posttranscription of .....	247
clinical trials of .....	171	production of proinflammatory cytokines in .....	243
pre-clinical studies of .....	171	proinflammatory cytokines modulate replication of .....	246
Fusion inhibitors .....	296	transcription of .....	247
based on gp41-fragment-remodeling peptides .....	296	vaccine strategies to .....	107
targeting dynamic supramolecular mechanism .....	296	virus diversity of .....	107
GAG-Pol polyprotein .....	73	HIV co-infection .....	95
expression of .....	73	CSF findings in .....	95
particle maturation of .....	80	lumbar puncture in .....	95
protein processing of .....	78	HIV coreceptors .....	5
GAG-Pol precursor protein .....	75	chemokine receptor as .....	5
into assembling virion .....	75	HIV infected patient .....	133
packaging of .....	75	inpatient care of .....	133
viral assembly of .....	75	HIV infection .....	261
Genital ulcer disease .....	227	immunotherapy of .....	261
gp41-C34-remodeling peptides .....	289	vaccination of .....	261
entry/fusion inhibitors based on .....	289	HIV proteins .....	250
Highly active antiretroviral therapy (HAART) .....	133	hijack proinflammatory cytokine signaling by .....	250
adverse reactions to .....	140	Nef as .....	250
and deaths .....	141	Tat as .....	251
and hepatitis C .....	140	Vpr as .....	251
and homelessness .....	134	HIV RNA Testing .....	184
and intensive care unit .....	141	by RNA assays .....	184
and mental health problems .....	134	HIV <sub>SF2</sub> gp120/MF59 vaccine .....	21
and substance abuse .....	134	phase I/II trial of .....	21
cardiovascular disease by .....	140	HIV vaccine .....	107
effect of age .....	140	deliver envelope cocktails for .....	109
future trends of .....	142	delivery vehicles of .....	111
in AIDS defining illnesses .....	137	design of .....	107
in care of HIV infected .....	133	in non-human primate system .....	108
in HIV associated malignancies .....	139	phase I safety trials in humans .....	110
in infectious diseases admissions .....	139	rationale of .....	107
		routes of .....	111
		testing envelope cocktails in non-human primates of .....	109
		testing of .....	107
		HIV/AIDS vaccine .....	18
		approval process of .....	18
		HIV-1 .....	43,54,61,87,111,207,223,249,277,332,349
		acquired immunity in .....	231
		alterations in other genes in .....	124

antiretroviral prophylaxis for .....	229	spermicidal microbicides in .....	230
antiretroviral therapy of .....	229	subtype diversity of .....	114
attenuation of .....	123	TAR decoys in .....	67
biological properties of .....	114	TAR RNA downregulates translation of .....	65
blood plasma viral load of .....	223	targeting TAR RNA to inactivate replication of .....	66
by anal intercourse .....	225	tat-mediated trans-activation of .....	61
by oro-genital intercourse .....	225	TAT-TAR RNA interactions for trans-activation of .....	61
by other sexual practices .....	226	translational control of .....	65
by sexual practices .....	225	transmission of .....	118
by vaginal intercourse .....	226	tropism of .....	121
CD4 <sup>+</sup> T cell depletion in .....	121	vaccines for .....	231
cell cycle disruption by .....	45	viral correlates of .....	113
cell tropism in .....	114	viral evolution in .....	55
cellular model defective for translation of .....	66	viral subtype of .....	113
cellular reservoir of .....	207	virulence of .....	118
chemokine receptor usage in .....	114	HIV-1 entry inhibitors .....	56
classification systems for biological phenotype of .....	120	implications for efficacy of .....	56
deletions in negative factor (NEF) gene .....	123	HIV-1 envelope .....	191
disease progression in .....	54	from codon-optimized .....	191
effect of treating STIs on transmission of .....	228	HIV-1 infection .....	303,345
effect on genital tract shedding .....	210,229	ADCC/NK cells/T cells in .....	35
effectiveness of HAART in .....	354	adherence/toxicities in .....	33
effects of VPR on gene expression in .....	43	altered movement in .....	34
factors affecting seminal viral load of .....	209,210	antiretroviral therapy of .....	33
factors affecting sexual transmission of .....	223	attraction of monocytes into brain in .....	310
hormonal contraception in .....	230	biologic determinants of .....	32
immune activation in .....	121	breast milk transmission of .....	32
implications for prevention of .....	223	cellular immune response in .....	37
implications of genetic variability of .....	120	clinical course of .....	32
in accessory organs MGT .....	352	clinical/immunologic aspects of .....	31
in anatomical reservoir .....	209	consequences of .....	303
in cell-free virus vs. cell-associated virus .....	208	difficulties with implementation of HAART in .....	33
in culture systems .....	211	HIV-1 entry into brain in .....	310
in dendritic cells .....	208	host immune response in .....	35
in reproductive tract of infected man .....	349	humoral immunity in .....	36
in semen .....	351	immunogenicity of Env in .....	36
in seminal leukocytes .....	208	in children .....	31
in spermatozoa .....	208	in utero transmission of .....	31
in testis .....	349	inflamed endothelium in .....	305
<i>in vivo</i> VPR mutations in .....	48	innate immune system in .....	35
induction of apoptosis in .....	47	intrapatum transmission of .....	32
laboratory methods for quantifying in semen of .....	210	maturation of IN tetramer in .....	81
mechanisms in MGT .....	352	maturation of RT heterodimer in .....	81
male genital tract as reservoir for .....	207	maturation PR homodimer in .....	80
macrophages in .....	54	mature viral enzymes in .....	80
micronutrient deficiencies in .....	231	migration by monocytes into brain in .....	310
modified oligonucleotides in .....	67	molecular mechanisms of .....	303
molecular techniques for .....	210	mother-to-child transmission of .....	31
natural immunity in .....	231	neutrophils/DCs in .....	35
NEF interaction with TAT in .....	91	obsterical factors in .....	32
other factors for .....	224	prevention of .....	33
pathogenesis of .....	43	T-cell death in .....	34
pathophysiology of in semen .....	207	T-cell depletion in .....	34
phenotype of .....	120	T cell regeneration in .....	36
post-transcriptional control of .....	65	thymus in .....	36
quasi-species of .....	225	treatment in male genital tract .....	345
relationship between M-tropism of .....	54	TREC <sub>s</sub> in .....	36
relative sexual infectivity of .....	209	viral kinetics of .....	33
ribozymes in .....	67	viral load in .....	33
role of VPR in .....	43	HIV-1 pol proteins .....	73
siRNAs in .....	67	maturation of .....	73
small molecules in .....	66		

packaging of .....	73	Live recombinant ALVAC-HIV (vCP1521) .....	26,27
viral protein processing of .....	80	phase I/II trial of .....	26
HIV-1 prophylactic vaccine trials .....	17	phase III trial of .....	27
evaluation of safety in .....	20	Low molecular weight CXCR4 antagonists .....	290
immunogenicity trial of .....	19	advantageous characters of T140-derived .....	293
in Thailand .....	17	anti-cancer-metastasis/anti-cancer cell progression	
national plan for .....	17	activities of .....	296
phase I of .....	19	anti-rheumatoid arthritis (RA) activity of .....	293
phase II of .....	20	based on cyclic pentapeptides .....	290
HIV-1 RAR RNA .....	61	Lumbar puncture (LP) .....	95
as target of molecular interactions .....	61	assessing response to treatment .....	96
HIV-1 subtypes .....	117	in clinical practice .....	96
transcriptional promoters in .....	117	indications of .....	96
HIV-1 viral protein gp 120 .....	277	in early syphilis .....	96
chemokine gene expression .....	277	Macrophages .....	308
effect of morphine .....	277	functions of .....	308
induced modulation of .....	277	in brain .....	308
in U373 astrocytoma cells .....	277	role in pathogenesis of HIV-associated dementia .....	309
HIV-1 Vif .....	339	Macrophage tropic HIV-1 .....	53
against cellular defense factor APOBEC3G .....	339	model for .....	57
against APOBEC3G'S destructive effects on viral		pathogenesis of .....	53
fitness .....	341	Male reproductive tract .....	346
HIV-2 infection .....	3	cells of .....	346
cellular receptors engagement in .....	7	immune status of .....	346
chemokine receptors in .....	3	tissues of .....	346
clinical data of .....	4	MIP-1 .....	364
epidemiologic data of .....	3	MIP-1 .....	364
HIV interaction with target cell in .....	4	Monocytes .....	303
molecular determinants of coreceptors usage in .....	7	across blood-brain barrier .....	309
virulence of .....	3	adhesion molecules in transendothelial migration of .....	306
IL-15 .....	261	in brain .....	308
advantages of .....	265	migration across basement membrane .....	307
as adjuvant .....	264	migration from tissues .....	308
as immunotherapeutic agent in AIDS patients .....	265	replenishment of brain macrophages by .....	309
biological effects of .....	262	transendothelial migration of .....	303
immune-enhancing effects of .....	265	Morphine .....	279
production in HIV infection .....	264	downregulates MIP-1 gene expression .....	279
protective role in viral/non-viral infections .....	264	suppresses MIP-1 secretion .....	280
regulation of production of .....	263	upregulates chemokine receptor CCR3 gene	
relative safety of .....	264	expression by .....	280
sources of .....	262	M-tropic R5 HIV-1 strains .....	55
IL-15 receptor .....	262	as cytopathic .....	55
Immune system .....	157	MVA-based HIV vaccines .....	172
interplay with viral vectors .....	157	clinical trials of .....	172
Inflammation .....	243	pre-clinical studies of .....	172
modulates phenotypic expression of CCR3/CCR5		Naloxone .....	283
by .....	280	effect on CCR5 gene expression .....	283
Leukemia .....	319	effect on MIP-1 secretion in U373 cells .....	283
development of .....	321	Nef .....	87
etiology of .....	320	in HIV infection .....	87,89
RAF associated signaling in .....	321	role in cellular activation .....	88
RAF/MEK/ERK inhibitors in treating .....	322	upregulation of transcription factors by expression of .....	90
viruses associated with .....	320		

Nef attenuated HIV-1 reporter .....	379	Reverse transcriptase assay .....	183
construction of .....	379	cost of .....	183
Neurosyphilis .....	95	evaluation of .....	183
CSF findings in .....	95	for plasma HIV-1 viral load monitoring .....	183
laboratory diagnosis of .....	95	precision of .....	187
laboratory parameters for .....	97	retrospective study of .....	187
Non-nucleoside reverse transcriptase inhibitor .....	271	sensitivity of .....	184
effects on immunological/virological outcome of .....	271	RNA-dependent protein kinase (PKR) .....	329
patients using .....	271	activation of .....	329
Non-ulcerative STIs .....	228	effect on lymphocytes by regulatory RNAs .....	329
Nucleocapsid protein .....	150	implications for immunomodulation in HIV .....	328
role of .....	150	infection .....	328
NYVAC-based HIV vaccines .....	172	SDF-1 .....	364
clinical trials of .....	172	Semen .....	207
patients using .....	271	fusion inhibitors in .....	214
pre-clinical studies of .....	172	non nucleoside reverse transcriptase inhibitors in .....	213
triple antiretroviral therapy by .....	271	nucleoside reverse transcriptase inhibitors in .....	212
Pediatric HIV infection .....	33	physiology of .....	207
difficulties with implementation of HAART in .....	33	protease inhibitors in .....	213
goals of antiretroviral therapy during .....	33	Sexually transmissible infections .....	227
Penis .....	349	Syphilis .....	95
Primary HIV-1 infection .....	223	CSF findings in .....	95
other factors for .....	224	effect on CNS .....	95
Primate lentiviruses .....	48	lumbar puncture in .....	95
Primer tRNA <sub>3</sub> <sup>Lys</sup> .....	147	TAR RNA .....	65
annealing of .....	147	inhibits translation by .....	65
structural bases of .....	147	TAR/Tat/P-TEF complex .....	62
post-transcriptional nucleoside modifications of .....	148	cellular interactions of .....	62
tertiary structure of .....	149	cellular models for defective tat-mediated trans- .....	63
to HIV-1 viral RNA .....	147	activation in .....	63
Protease (PR) .....	73	components of .....	62
autocatalytic release of .....	79	TRBP .....	65
Protease inhibitor .....	271	translation from TAR RNA .....	65
effects on immunological/virological outcome .....	271	TRNA/viral RNA initiation complex .....	152
of .....	271	structure of .....	152
RANTES .....	364	Unattenuated reporter viruses .....	379
Recombinant HIV-1 infection .....	379	Urethra .....	349
expression of reporter genes .....	379	Vascular endothelium .....	304
Recombinant subtype B (HIV-1 <sub>SF2</sub> gp120) .....	22	migration by monocytes across .....	306
phase I/II trial of combinations of .....	22	structure of .....	304
Regulatory RNAs .....	332	Viral vector-based products .....	164
in lymphocytes activated by synthetic peptides of .....	332	coding capacity of .....	164
HIV-1 .....	332	duration of expression of .....	165
Related viruses .....	319	safety/toxicity of .....	165
association with leukemia .....	319	vector tropism/targeting by .....	167
RAF signaling of .....	319	Vpr attenuated reporter viruses .....	379